


CALGB (STUDY 1)

9.3-year median OS with REVLIMID Maintenance (secondary endpoint)²

MEDIAN OS DESCRIPTIVE ANALYSIS



Descriptive analysis of overall survival data with a cutoff date of February 1, 2016. Median follow-up time was 81.6 months for CALGB and 96.7 months for IFM. Neither CALGB nor IFM were powered to evaluate OS.

CALGB, Cancer and Leukemia Group B; IFM, Intergroupe Francophone du Myélome, LLC; NE, not evaluable; OS, overall survival.